Methicillin-resistant Staphylococcus aureus bacteremia at a university hospital in Japan

Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients withStaphylococcus aureusBacteremia: A Meta-analysis of Observational Studies

“…Of 377 studies retrieved from the PubMed query and two studies retrieved from bibliographic review, only 14 studies ultimately met the criteria to be incorporated into the final analyses (Figure ) . These studies were published from 2011 to 2014, with 1677 unique patients representing geriatric and unspecified inpatients (Table ) . Treatment failure was an outcome of seven studies, all of which used a definition of treatment failure that included mortality and persistent bacteremia .…”

“…8,[13][14][15][16][17][18][19][20][21][22][23][24][25] These studies were published from 2011 to 2014, with 1677 unique patients representing geriatric 19 and unspecified inpatients ( Table 1). 8,[13][14][15][16][17][18][20][21][22][23][24][25] Treatment failure was an outcome of seven studies, all of which used a definition of treatment failure that included mortality and persistent bacteremia. 8, 14, 16-18, 22, 23 Trough concentration was reported as a dichotomous variable in eight studies and a continuous variable in eight studies, with two studies reporting both continuous and dichotomous variables.…”

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

“…In several recent studies involving consecutive patients with either SAB (MSSA and MRSA) (12,31,32,(56)(57)(58)(59)(60) or only MRSA bacteremia (61)(62)(63)(64)(65)(66), common primary clinical foci or sources of infection are vascular catheter-related infections, SSTIs, pleuropulmonary infections, osteoarticular infections, and IE (Table 2). These common primary clinical foci represent a subset of the common general clinical manifestations of S. aureus infections.…”

Microbiological Improvement by Antimicrobial Stewardship Program and Infection Control in Japan

“…Especially, resistant P. aeruginosa for carbapenems including imipenem/cilastatin and meropenem, aztreonam and fluoroquinolones including levofloxacin and ciprofloxacin were significantly decreased. As we have previously reported, the occurrences of drugresistant strains including MDRP and related infectious diseases, such as pneumonia and blood stream infection (BSI), were big issues in Japan [6,7].…”